In enzalutamide-treated prostate cancer cells, GR induces the expression of cAMP pathway-associated genes, leading to the nuclear accumulation of the cAMP-dependent protein kinase A catalytic subunit (PKA-c) (109). This evidence concerns the gene NR3C1 and prostate carcinoma.